Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/46159 |
Resumo: | Epilepsy is the most common serious neurological disorder worldwide. Approximately 70% of patients with epilepsy have their seizures controlled by clinical and pharmacological treatment. This research evaluated the possible influence of interchangeability among therapeutic equivalents of LTG on the clinical condition and quality of life of refractory epileptic patients. The study was divided into three periods of 42 days, and an equivalent therapeutic LTG randomly dispensed for each period (two similars - formulations A and B, and the reference product - formulation C). The mean dose of LTG was 5.5 mg/kg/day. The presence of side effects tends to have a greater deleterious effect on quality of life of refractory epileptics compared to variations in number of seizures or changes in plasma concentrations. The results showed that independently of the drug prescribed, interchangeability among therapeutic equivalents can negatively impact epilepsy control. |
id |
USP-31_38e2346f4f139c067338697a38150ae4 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/46159 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of lifeEpilepsy^i1^streatmLamotrigine^i1^stherapeutic equivaleDrugs^i1^sinterchangeabilEpilepsy is the most common serious neurological disorder worldwide. Approximately 70% of patients with epilepsy have their seizures controlled by clinical and pharmacological treatment. This research evaluated the possible influence of interchangeability among therapeutic equivalents of LTG on the clinical condition and quality of life of refractory epileptic patients. The study was divided into three periods of 42 days, and an equivalent therapeutic LTG randomly dispensed for each period (two similars - formulations A and B, and the reference product - formulation C). The mean dose of LTG was 5.5 mg/kg/day. The presence of side effects tends to have a greater deleterious effect on quality of life of refractory epileptics compared to variations in number of seizures or changes in plasma concentrations. The results showed that independently of the drug prescribed, interchangeability among therapeutic equivalents can negatively impact epilepsy control.Epilepsia é o distúrbio neurológico grave mais comum no mundo todo. Aproximadamente 70% dos pacientes com epilepsia têm suas crises controladas com tratamento clínico e farmacológico. Esta pesquisa avaliou a possível interferência da intercambialidade entre equivalentes terapêuticos da lamotrigina na condição clínica e na qualidade de vida dos pacientes com epilepsia refratária. O estudo foi dividido em três períodos de 42 dias e em cada período foi dispensado um equivalente terapêutico, aleatoriamente (dois similares - formulação A e B e o medicamento de referência - formulação C). A dose média de lamotrigina foi de 5,5 mg/kg/dia. A ocorrência de efeitos colaterais tende a ser mais decisiva para a redução da qualidade de vida em epilepsia refratária em relação às variações no número de crises ou alterações nas concentrações plasmáticas. Os resultados demonstram que, independentemente do medicamento prescrito, a intercambialidade entre equivalentes terapêuticos pode interferir no sucesso do controle da epilepsia.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2012-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/4615910.1590/S1984-82502012000100011Brazilian Journal of Pharmaceutical Sciences; Vol. 48 Núm. 1 (2012); 95-102Brazilian Journal of Pharmaceutical Sciences; v. 48 n. 1 (2012); 95-102Brazilian Journal of Pharmaceutical Sciences; Vol. 48 No. 1 (2012); 95-1022175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/46159/49782Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessGirolineto, Beatriz Maria PereiraJunior, Veriano AlexandreSakamoto, Américo CeikiPereira, Leonardo Régis Leira2012-10-18T17:39:06Zoai:revistas.usp.br:article/46159Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2012-10-18T17:39:06Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life |
title |
Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life |
spellingShingle |
Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life Girolineto, Beatriz Maria Pereira Epilepsy^i1^streatm Lamotrigine^i1^stherapeutic equivale Drugs^i1^sinterchangeabil |
title_short |
Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life |
title_full |
Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life |
title_fullStr |
Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life |
title_full_unstemmed |
Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life |
title_sort |
Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life |
author |
Girolineto, Beatriz Maria Pereira |
author_facet |
Girolineto, Beatriz Maria Pereira Junior, Veriano Alexandre Sakamoto, Américo Ceiki Pereira, Leonardo Régis Leira |
author_role |
author |
author2 |
Junior, Veriano Alexandre Sakamoto, Américo Ceiki Pereira, Leonardo Régis Leira |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Girolineto, Beatriz Maria Pereira Junior, Veriano Alexandre Sakamoto, Américo Ceiki Pereira, Leonardo Régis Leira |
dc.subject.por.fl_str_mv |
Epilepsy^i1^streatm Lamotrigine^i1^stherapeutic equivale Drugs^i1^sinterchangeabil |
topic |
Epilepsy^i1^streatm Lamotrigine^i1^stherapeutic equivale Drugs^i1^sinterchangeabil |
description |
Epilepsy is the most common serious neurological disorder worldwide. Approximately 70% of patients with epilepsy have their seizures controlled by clinical and pharmacological treatment. This research evaluated the possible influence of interchangeability among therapeutic equivalents of LTG on the clinical condition and quality of life of refractory epileptic patients. The study was divided into three periods of 42 days, and an equivalent therapeutic LTG randomly dispensed for each period (two similars - formulations A and B, and the reference product - formulation C). The mean dose of LTG was 5.5 mg/kg/day. The presence of side effects tends to have a greater deleterious effect on quality of life of refractory epileptics compared to variations in number of seizures or changes in plasma concentrations. The results showed that independently of the drug prescribed, interchangeability among therapeutic equivalents can negatively impact epilepsy control. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/46159 10.1590/S1984-82502012000100011 |
url |
https://www.revistas.usp.br/bjps/article/view/46159 |
identifier_str_mv |
10.1590/S1984-82502012000100011 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/46159/49782 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 48 Núm. 1 (2012); 95-102 Brazilian Journal of Pharmaceutical Sciences; v. 48 n. 1 (2012); 95-102 Brazilian Journal of Pharmaceutical Sciences; Vol. 48 No. 1 (2012); 95-102 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222910702419968 |